Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Glucose Monitoring, Insulin Delivery

April 09, 2019

New Medtronic/BCBS CGM Outcomes-Based Contract

Here is a brief preview of this blast: Medtronic announced it has signed an outcomes-based contract (OBC) with BCBS of Minnesota for the standalone Guardian Connect CGM. According to the press release, the OBC is based on time-in-range metrics. In return, Guardian Connect will be distributed through the BCBS Minnesota pharmacy benefit. While the press release does not specify, it is believed that both insulin-dependent T1DM and T2DM patients are eligible. Below, FENIX provides thoughts on the Medtronic CGM OBC and how it could impact other CGM manufacturers, notably Dexcom and Abbott.